[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA26494A1 - Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. - Google Patents

Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.

Info

Publication number
MA26494A1
MA26494A1 MA25064A MA25064A MA26494A1 MA 26494 A1 MA26494 A1 MA 26494A1 MA 25064 A MA25064 A MA 25064A MA 25064 A MA25064 A MA 25064A MA 26494 A1 MA26494 A1 MA 26494A1
Authority
MA
Morocco
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
protease inhibitors
novel protease
Prior art date
Application number
MA25064A
Other languages
English (en)
Inventor
W Marquis Robert
Ru Yu
F Veber Daniel
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA26494A1 publication Critical patent/MA26494A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
MA25064A 1997-05-08 1998-05-06 Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. MA26494A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4686597P 1997-05-08 1997-05-08

Publications (1)

Publication Number Publication Date
MA26494A1 true MA26494A1 (fr) 2004-12-20

Family

ID=21945814

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25064A MA26494A1 (fr) 1997-05-08 1998-05-06 Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.

Country Status (18)

Country Link
US (1) US6369077B1 (fr)
EP (1) EP0991753A4 (fr)
JP (1) JP2001525809A (fr)
KR (1) KR20010012316A (fr)
CN (1) CN1255162A (fr)
AU (1) AU7288598A (fr)
BR (1) BR9808502A (fr)
CA (1) CA2289010A1 (fr)
CO (1) CO4950617A1 (fr)
HU (1) HUP0001285A3 (fr)
IL (1) IL131661A0 (fr)
MA (1) MA26494A1 (fr)
NO (1) NO995433L (fr)
PE (1) PE73799A1 (fr)
PL (1) PL336625A1 (fr)
TR (1) TR199902752T2 (fr)
WO (1) WO1998050534A1 (fr)
ZA (1) ZA983843B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001399T2 (tr) * 1997-11-18 2000-11-21 Teijin Limited Siklik amin türevleri ve ilaç olarak kullanımları.
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
CO5180541A1 (es) * 1998-12-23 2002-07-30 Smithkline Beechman Corp Inhibidores de proteasa del tipo de 1,3-diaminocetonas con anillo de 8-14 miembros
WO2000069815A1 (fr) * 1999-05-13 2000-11-23 Teijin Limited Derives d'amines cycliques ureido-substituees et leur utilisation en tant que medicament
ATE277903T1 (de) 1999-05-14 2004-10-15 Bristol Myers Squibb Pharma Re Zyklische aminderivate und ihre verwendung
DK1179341T3 (da) * 1999-05-18 2006-03-27 Teijin Ltd Lægemidler eller forebyggende midler mod sygdomme der er associeret med chemokiner
WO2001010439A1 (fr) * 1999-08-04 2001-02-15 Teijin Limited Antagonistes d'amine cyclique ccr3
WO2001042208A1 (fr) * 1999-12-08 2001-06-14 Teijin Limited Antagonistes du recepteur ccr5 de la cycloamine
ES2225297T3 (es) 1999-12-21 2005-03-16 Smithkline Beecham Corporation Antagonistas del receptor de urotensina ii.
AU780006B2 (en) 2000-03-06 2005-02-24 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
SK13632002A3 (sk) * 2000-03-21 2003-02-04 Smithkline Beecham Corporation C1-6-alkyl-4-amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
US6410566B1 (en) 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
US8211916B2 (en) 2000-06-20 2012-07-03 Wayne State University N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith
WO2001098266A2 (fr) 2000-06-20 2001-12-27 Wayne State University Analogues de 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine a substitution n-et o- et methodes therapeutiques contre des troubles du systeme nerveux central (snc)
US6395753B1 (en) * 2001-08-30 2002-05-28 Kowa Co., Ltd. Cyclic amine compounds and pharmaceutical composition containing the same
RU2315051C2 (ru) 2001-12-28 2008-01-20 Акадиа Фармасьютикалз, Инк. Спироазациклические соединения, способ ингибирования активности или активации серотонинового 5-нт2а рецептора, способ лечения болезненного состояния, связанного с серотониновым 5-нт2а рецептором, и их применение
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンｋ阻害剤として有用なシクロアルキルケトアミド誘導体
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004000808A2 (fr) 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. Derives de piperidine substitues en n en tant qu'agents recepteurs de la serotonine
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
KR100962972B1 (ko) 2002-07-26 2010-06-09 주식회사유한양행 1-페닐피페리딘-3-온 유도체 및 그의 제조방법
ES2367135T3 (es) 2003-01-16 2011-10-28 Acadia Pharmaceuticals Inc. Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilzados como agentes terapéuticos para enfermedades neurodegenerativas.
US20040192674A1 (en) * 2003-02-14 2004-09-30 Marquis Robert W. Cathepsin L inhibitors
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US8017791B2 (en) 2003-03-28 2011-09-13 Wayne State University Tri-substituted 2-benzhydryl-5-benzylamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel, 3,6-disubstituted pyran derivatives
WO2005105075A1 (fr) 2004-04-16 2005-11-10 Wayne State University À trois substitut 2-benzhydryl-5- benzlamino- tétrahydropyran-4-ol et 6-benzhydryl-4-benzylamino-analogues tétrahydropyran-3-ol et nouveaux dérivés pyranne disubstitué 3,6
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
JP2008512461A (ja) * 2004-09-07 2008-04-24 スミスクライン・ビーチャム・コーポレイション 新規化合物
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
CN101035759B (zh) 2004-09-27 2011-06-15 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形
CN102558075A (zh) 2004-12-03 2012-07-11 先灵公司 作为cb1拮抗剂的取代哌嗪
MX2008002363A (es) * 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
US8067415B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053498A1 (fr) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composés pouvant être employés en tant qu'antagonistes de ccr2
WO2007053495A2 (fr) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composes utiles en tant qu’antagonistes de ccr2
AR058985A1 (es) * 2006-01-13 2008-03-05 Schering Corp Diaril piperidinas como moduladores de cb1.
AR059021A1 (es) * 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
JPWO2008029924A1 (ja) * 2006-09-08 2010-01-21 大日本住友製薬株式会社 環状アミノアルキルカルボキサミド誘導体
PL2134330T3 (pl) 2007-03-19 2013-10-31 Acadia Pharm Inc Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
US8686152B2 (en) 2010-03-10 2014-04-01 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
CN102933214A (zh) * 2010-03-10 2013-02-13 詹森药业有限公司 可用作二肽基肽酶-1(dpp-1)抑制剂的4，4-二取代的哌啶衍生物
AU2015240519B2 (en) 2014-04-04 2019-08-15 X-Rx, Inc. Substituted spirocyclic inhibitors of autotaxin
CA2992728A1 (fr) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Procedes de preparation de n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-2-methylpropyloxy)phenylmethyl)carbamide, son sel de tartrate et sa forme polymorphe c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (fr) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Association de pimavansérine et de modulateurs du cytochrome p450
WO2018118626A1 (fr) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer
WO2018200977A1 (fr) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavansérine pour le traitement d'un trouble de contrôle des impulsions
EP3675827A1 (fr) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations de pimavansérine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2804416A1 (de) 1978-02-02 1979-08-09 Boehringer Mannheim Gmbh Neue purin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
ES482439A0 (es) 1978-07-18 1980-04-01 Hoechst Ag Procedimiento para la preparacion de nuevos derivados de 1-(4-aminopiperidino)-3,4-dihidroisoquinoleina.
US4301151A (en) 1979-11-27 1981-11-17 Merck & Co., Inc. Long-lasting agonists of enkephalin
US4443461A (en) 1981-09-10 1984-04-17 John Wyeth & Brother Limited N-[2-[[1-[1H-Indolylalkyl- or oxoalkyl]-4-piperidinyl]-amino]-2-oxoethyl]-arylcarboxamide derivatives
US4680283A (en) * 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
DK386089A (da) 1988-08-12 1990-02-13 Japan Tobacco Inc Katekolderivater
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
US5204462A (en) 1990-03-30 1993-04-20 Japan Tobacco, Inc. 4h-3,1-benzoxazin-4-one derivative
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
WO1994027967A1 (fr) * 1993-05-26 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Nouveaux composes
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.

Also Published As

Publication number Publication date
US6369077B1 (en) 2002-04-09
CO4950617A1 (es) 2000-09-01
NO995433D0 (no) 1999-11-05
TR199902752T2 (xx) 2000-06-21
EP0991753A1 (fr) 2000-04-12
HUP0001285A2 (hu) 2000-09-28
CN1255162A (zh) 2000-05-31
WO1998050534A1 (fr) 1998-11-12
PL336625A1 (en) 2000-07-03
IL131661A0 (en) 2001-01-28
ZA983843B (en) 1998-11-09
KR20010012316A (ko) 2001-02-15
BR9808502A (pt) 2000-05-23
NO995433L (no) 1999-11-05
PE73799A1 (es) 1999-10-22
CA2289010A1 (fr) 1998-11-12
EP0991753A4 (fr) 2001-07-11
HUP0001285A3 (en) 2000-10-30
AU7288598A (en) 1998-11-27
JP2001525809A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
MA26494A1 (fr) Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA24529A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant .
FR2748026B1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA26451A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26743A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26551A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26487A1 (fr) Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26424A1 (fr) Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26654A1 (fr) Pyrrolopyrimidines nouvelles procede pour leur preparation et compositions pharmaceutiques les contenant
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26686A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2890A1 (fr) 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2866A1 (fr) 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.